PMID- 31389626
OWN - NLM
STAT- MEDLINE
DCOM- 20200914
LR  - 20200914
IS  - 1440-1746 (Electronic)
IS  - 0815-9319 (Linking)
VI  - 35
IP  - 3
DP  - 2020 Mar
TI  - Short-term and long-term outcomes of indigo naturalis treatment for inflammatory 
      bowel disease.
PG  - 412-417
LID - 10.1111/jgh.14823 [doi]
AB  - BACKGROUND AND AIM: Indigo naturalis (IN) is a traditional Chinese herbal 
      medicine reported to be effective in inducing remission in ulcerative colitis 
      (UC). We conducted a retrospective observational study to investigate the 
      efficacy and safety of IN for induction and maintenance therapy in patients with 
      inflammatory bowel disease. METHODS: Data were collected from the electric 
      medical records of patients with inflammatory bowel disease who had started IN 
      treatment between March 2015 and April 2017 at Kyushu University Hospital. 
      Clinical response and remission rates were assessed based on the clinical 
      activity index determined by Rachmilewitz index or Crohn's disease (CD) activity 
      index. Cumulative IN continuation rates were estimated using the Kaplan-Meier 
      method. Overall adverse events (AEs) during follow-up were also analyzed. 
      RESULTS: Seventeen UC patients and eight CD patients were enrolled. Clinical 
      response and remission rates at week 8 were 94.1% and 88.2% in UC patients and 
      37.5% and 25.0% in CD patients, respectively. Clinical remission rates, as 
      assessed through non-responders imputation analyses at weeks 52 and 104, were 
      76.4% and 70.4% in UC patients and 25.0% and 25.0% in CD patients, respectively. 
      Ten patients (40%) experienced AEs during follow-up. Three patients (12%) 
      experienced severe AEs, including acute colitis requiring hospitalization in two 
      patients and acute colitis with intussusception requiring surgery in one patient. 
      CONCLUSIONS: Indigo naturalis showed favorable therapeutic efficacy in UC, 
      whereas its therapeutic efficacy in CD appeared to be modest. The risk of severe 
      AEs should be recognized for IN treatment.
CI  - (c) 2019 Journal of Gastroenterology and Hepatology Foundation and John Wiley & 
      Sons Australia, Ltd.
FAU - Matsuno, Yuichi
AU  - Matsuno Y
AUID- ORCID: 0000-0002-1973-2573
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Hirano, Atsushi
AU  - Hirano A
AUID- ORCID: 0000-0002-4791-4550
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Torisu, Takehiro
AU  - Torisu T
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Okamoto, Yasuharu
AU  - Okamoto Y
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Fuyuno, Yuta
AU  - Fuyuno Y
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Fujioka, Shin
AU  - Fujioka S
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Umeno, Junji
AU  - Umeno J
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Moriyama, Tomohiko
AU  - Moriyama T
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Nagai, Shuntaro
AU  - Nagai S
AD  - Department of Surgery and Oncology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Hori, Yoshifumi
AU  - Hori Y
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Fujiwara, Minako
AU  - Fujiwara M
AD  - Department of Anatomic Pathology, Graduate School of Medical Sciences, Kyushu 
      University, Fukuoka, Japan.
FAU - Kitazono, Takanari
AU  - Kitazono T
AD  - Department of Medicine and Clinical Science, Graduate School of Medical Sciences, 
      Kyushu University, Fukuoka, Japan.
FAU - Esaki, Motohiro
AU  - Esaki M
AD  - Department of Endoscopic Diagnostics and Therapeutics, Saga University Hospital, 
      Saga, Japan.
LA  - eng
PT  - Journal Article
DEP - 20190826
PL  - Australia
TA  - J Gastroenterol Hepatol
JT  - Journal of gastroenterology and hepatology
JID - 8607909
RN  - 0 (Drugs, Chinese Herbal)
RN  - D3741U8K7L (Indigo Carmine)
SB  - IM
MH  - Adult
MH  - Drugs, Chinese Herbal/adverse effects/*therapeutic use
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Indigo Carmine/*chemistry
MH  - Inflammatory Bowel Diseases/*drug therapy/mortality
MH  - Maintenance Chemotherapy
MH  - Male
MH  - *Phytotherapy
MH  - Remission Induction
MH  - Survival Rate
MH  - Time Factors
MH  - Treatment Outcome
MH  - Young Adult
OTO - NOTNLM
OT  - Crohn's disease
OT  - Qing-Dai
OT  - indigo naturalis
OT  - inflammatory bowel disease
OT  - ulcerative colitis
EDAT- 2019/08/08 06:00
MHDA- 2020/09/15 06:00
CRDT- 2019/08/08 06:00
PHST- 2019/05/15 00:00 [received]
PHST- 2019/07/24 00:00 [revised]
PHST- 2019/08/03 00:00 [accepted]
PHST- 2019/08/08 06:00 [pubmed]
PHST- 2020/09/15 06:00 [medline]
PHST- 2019/08/08 06:00 [entrez]
AID - 10.1111/jgh.14823 [doi]
PST - ppublish
SO  - J Gastroenterol Hepatol. 2020 Mar;35(3):412-417. doi: 10.1111/jgh.14823. Epub 
      2019 Aug 26.